v2ray官网打不开了-outline

Quarterly Review

Sales and earnings growth at Pharmaceuticals

Sales gains at Crop Science and Animal Health

netfits云墙安卓版官网

netfits云墙安卓版官网 (+1.2%)

EBITDA before special items

€2.2 billion (+4.1%)

Download Full Report (PDF, 0.6MB) Bayer Newsletter Investor Conference Call Share

v2ray官网打不开了-outline

Sales
EBITDA Before Special Items
Core Earnings per Share

+1.2%

Following the deconsolidation of Covestro, the Bayer Group’s sales rose by 1.2% (Fx & portfolio adj.) to €8.0 billion in the third quarter of 2017.

View all Q3 key figures

+4.1%

Group EBITDA before special items increased by 4.1% to €2,204 million.

View all Q3 key figures

netpas云墙安卓

非法经营网络翻墙软件获利兄弟俩领刑受罚-中国 ...:2021-4-4 · 经验证，曾某恒和曾某宁销售的网络加速器中，有五款加速器软件为国家严厉打击的非法电视网络接收设备。长洲区法院经审理后认为，被告人曾某恒、曾某宁违反国家规定，伕理销售国家严厉打击的非法电视网络接收设备，严重扰乱市场秩序，情节严重，二人行为已触犯刑律，构成非法经营罪。

View all Q3 key figures

东北网2021年07月08日新闻汇总:楼市调整加速：开发商爱打价格牌炒家降价套现 2021-07-08 11:11 [452][生活频道] 加息后房贷利息破近十年最高纪录 2021-07-08 11:11 [453][东北网社会] 传董事长儿子被劫持歹徒持枪索700万美元(图) 2021-07-08 11:10 [454][东北网社会]

Pharmaceuticals

Sales of Pharmaceuticals increased by 2.3 percent (Fx & portfolio adj.) to €4,065 million in the third quarter of 2017. Our key growth products Xarelto™, Eylea™, Xofigo™, Stivarga™ and Adempas™ once again delivered strong performance, with their combined sales rising by 13.2 percent (Fx adj.) to €1,522 million (Q3 2016: €1,395 million).

Find out more

Consumer Health

Sales of Consumer Health in the third quarter of 2017 fell by 2.9 percent (Fx & portfolio adj.) to €1,320 million. The decline in sales in North America was largely due to the market environment remaining challenging in the United States.

netpas云墙安卓

Crop Science

Crop Science posted sales of €2,031 million in the third quarter of 2017 (Fx & portfolio adj. + 2.7 percent). Crop Protection / Seeds registered gains on a currency- and portfolio-adjusted basis that resulted particularly from gratifying development in the Asia / Pacific and North America regions.

Find out more